Compound ID | 2795
MEndoB
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Natural product; Direct acting; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Peptidoglycan hydrolase; cleaves specific peptidoglycan bonds |
| Target Pathogen: | Active against in methicillin-resistant and -susceptible Staphylococcus aureus and Staphylococcus epidermidis |
| Description: | Molecularly engineered and rationally designed chimeric peptidoglycan hydrolase of staphylococcal origin; shows synergistic effect with oxacillin, flucloxacillin, cefazolin; shows additive effect with vancomycin, levofloxacin, and daptomycin; has high activity in human and animal sera, and human blood |
| Institute where first reported: | Micreos Pharmaceuticals AG, Baar, Zug, Switzerland |
| Year first mentioned: | 2024 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://journals.asm.org/doi/10.1128/mbio.02540-23 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.